Factors influencing the episode duration and the anatomical and functional outcome in cases of acute central serous chorioretinopathy

Abstract

ObjectiveTo investigate the factors affecting the duration of subretinal fluid (SRF) resolution and their correlation with the final anatomical and functional outcome in cases of treatment naïve acute central serous chorioretinopathy (CSCR).Methods and analysisWe retrospectively studied 93 eyes of 93 patients diagnosed with treatment naïve acute CSCR presenting within 30 days of onset of symptoms. The eyes were divided into two groups (1 and 2) based on the duration of SRF resolution; which was ≤3 months in group 1 and >3 months in group 2. Demographic and medical history, and spectral domain optical coherence tomography features were noted and their association with duration for SRF resolution, final central macular thickness (CMT) and final best-corrected visual acuity (BCVA) were studied. All the patients were prescribed topical non-steroidal anti-inflammatory drug for 1 month at the diagnosis of CSCR.ResultsLonger duration of symptoms, female gender and baseline OCT factors like hyper-reflective dots and retinal pigment epithelial bumps were associated with longer duration for SRF resolution (p<0.001, p=0.04, p=0.001 and p=0.01, respectively). The SRF resolution time had strong correlations with the final CMT (r=−0.589, p<0.001) and final BCVA in logarithm of minimum angle of resolution (LogMAR) (r=+0.599, p<0.001). Group 2 eyes had worse final BCVA and thinner final CMT than Group 1 (both p<0.001). The final CMT of the patients of Group 1 was statistically thinner than the normal population (p<0.001).ConclusionPatient’s baseline clinicodemographic and OCT features can be used to predict the course and visual outcome in cases of treatment naïve acute idiopathic CSCR.

Effects of Ketoconazole On Clinical Recovery In Central Serous Chorioretinopathy

“…These cut-off values are close to the 75 th percentiles of our study's predictive values: choroidal thickness of >450 µm and age of >45 years. In contrast to some reports, we did not observe any association between either baseline BCVA or CST and the disease episode length [24,25].…”

Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis

“…Two studies were cohort studies of eyes with CSC treated with any topical NSAIDs (Brandl et al, 2014; Parajuli & Joshi, 2020). Brandl et al (2014) conducted a prospective cohort study of eyes with acute CSC treated with topical NSAIDs QID (not specified further) in combination with topical brinzolamide QID for 3 months and seven of 10 patients also received oral acetazolamide 125 mg QID.…”

“…At 3 months of follow‐up, subretinal fluid was observed in 6 of 11 eyes (Brandl et al, 2014). Parajuli and Joshi (2020) conducted a retrospective cohort study of eyes with acute CSC treated with topical ketorolac 0.4% QID for 1 month. This was a study designed to evaluate the predictive ability of any baseline factors on the time to resolution of subretinal fluid (Parajuli & Joshi, 2020).…”

“…Parajuli and Joshi (2020) conducted a retrospective cohort study of eyes with acute CSC treated with topical ketorolac 0.4% QID for 1 month. This was a study designed to evaluate the predictive ability of any baseline factors on the time to resolution of subretinal fluid (Parajuli & Joshi, 2020). Of 93 cases with acute CSC, 67 (72%) experienced resolution of subretinal fluid ≤3 months, and the remaining 26 (28%) had a resolution of subretinal fluid ≤7 months.…”

Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy

“…Inconsistent with some reports, either baseline BCVA or CST was not associated with the disease episode length. 33 , 34 …”